Which Peptides Are FDA Approved?

Over 80 peptide-based medications have received FDA approval as of 2026, with notable examples including semaglutide (Wegovy, Ozempic) for weight management and diabetes, tirzepatide (Mounjaro, Zepbound) for diabetes and weight management, insulin and its analogs for diabetes, bremelanotide (Vyleesi) for hypoactive sexual desire disorder, tesamorelin (Egrifta) for HIV-associated lipodystrophy, calcitonin for osteoporosis, and vasopressin analogs for various conditions. These approved peptides have undergone rigorous Phase I through Phase III clinical trials demonstrating safety and efficacy for their specific indications.

GLP-1 and Dual Incretin Receptor Agonists

The GLP-1 receptor agonist class represents some of the most commercially successful peptide medications in history, generating tens of billions of dollars in annual revenue and transforming the treatment of obesity and diabetes.

Semaglutide

Brand names: Ozempic (diabetes), Wegovy (weight management), Rybelsus (oral, diabetes)
Manufacturer: Novo Nordisk
FDA approval dates: Ozempic (2017), Rybelsus (2019), Wegovy (2021)
Indications: Type 2 diabetes, chronic weight management, cardiovascular risk reduction
Mechanism: GLP-1 receptor agonist

Tirzepatide

Brand names: Mounjaro (diabetes), Zepbound (weight management)
Manufacturer: Eli Lilly
FDA approval dates: Mounjaro (2022), Zepbound (2023)
Indications: Type 2 diabetes, chronic weight management
Mechanism: Dual GIP/GLP-1 receptor agonist (first in class)

Other GLP-1 Agonists

Liraglutide (Victoza, Saxenda): Approved for diabetes (2010) and weight management (2014)
Exenatide (Byetta, Bydureon): The first GLP-1 agonist, approved 2005
Dulaglutide (Trulicity): Approved for type 2 diabetes (2014)
Lixisenatide (Adlyxin): Approved for type 2 diabetes (2016)

Insulin and Insulin Analogs

Insulin was the first peptide medication, revolutionizing the treatment of diabetes when it was introduced in 1922. Today, numerous insulin formulations are FDA-approved, each designed for specific clinical needs.

Categories of Insulin

Rapid-acting: Insulin lispro (Humalog), insulin aspart (NovoLog), insulin glulisine (Apidra)
Short-acting: Regular human insulin (Humulin R, Novolin R)
Intermediate-acting: NPH insulin (Humulin N, Novolin N)
Long-acting: Insulin glargine (Lantus, Toujeo), insulin detemir (Levemir), insulin degludec (Tresiba)
Concentrated: Insulin lispro U-200 (Humalog U-200), insulin glargine U-300 (Toujeo)

Insulin remains the cornerstone of type 1 diabetes treatment and is essential for many people with advanced type 2 diabetes. Modern insulin analogs have dramatically improved glycemic control and quality of life compared to earlier formulations.

Peptides for Hormonal and Metabolic Conditions

Tesamorelin (Egrifta)

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to produce growth hormone naturally, rather than supplying exogenous GH directly. This makes it the only FDA-approved GHRH analog currently on the market.

Growth Hormone

Recombinant human growth hormone (somatropin) is approved under multiple brand names including Genotropin, Humatrope, Norditropin, and Nutropin. While technically a protein rather than a peptide (191 amino acids), it is closely related to the peptide field. Approved indications include growth hormone deficiency in children and adults, Turner syndrome, chronic kidney disease in children, and short bowel syndrome.

Calcitonin

Calcitonin, a 32-amino acid peptide hormone, is approved for the treatment of postmenopausal osteoporosis and Paget's disease of bone. It works by inhibiting osteoclast activity, thereby reducing bone resorption. Available as both a nasal spray (Miacalcin, Fortical) and injection, though its use has declined with the availability of newer osteoporosis treatments.

Peptides for Reproductive and Sexual Health

Bremelanotide (Vyleesi)

Bremelanotide, approved in 2019, is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. It represents the first FDA-approved peptide specifically for female sexual dysfunction.

GnRH Agonists and Antagonists

Leuprolide (Lupron): A GnRH agonist approved for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty
Goserelin (Zoladex): GnRH agonist for prostate cancer and breast cancer
Cetrorelix (Cetrotide): GnRH antagonist used in assisted reproduction to prevent premature ovulation
Degarelix (Firmagon): GnRH antagonist for advanced prostate cancer

Peptides in Diagnostic and Emergency Medicine

Vasopressin and Analogs

Vasopressin (antidiuretic hormone) and its analogs have multiple FDA-approved uses. Desmopressin (DDAVP) is approved for diabetes insipidus, nocturnal enuresis, and certain bleeding disorders. Vasopressin itself is used in emergency medicine for vasodilatory shock and cardiac arrest protocols.

Octreotide (Sandostatin)

Octreotide is a synthetic somatostatin analog approved for the treatment of acromegaly, carcinoid tumors, and vasoactive intestinal peptide-secreting tumors. It works by inhibiting the release of growth hormone, insulin, and glucagon.

Peptides in Pipeline (Late-Stage Development)

Numerous peptides are in late-stage clinical trials and may receive FDA approval in the coming years. These include oral GLP-1 formulations with improved bioavailability, next-generation multi-receptor agonists targeting GLP-1, GIP, and glucagon receptors simultaneously, novel antimicrobial peptides for drug-resistant infections, and peptide-drug conjugates for targeted cancer therapy. The peptide pharmaceutical pipeline is one of the most active in the industry, with hundreds of candidates at various stages of development.

The Bottom Line

FDA-approved peptide medications cover a wide range of conditions from diabetes and obesity to cancer, osteoporosis, and sexual health disorders. These approved peptides have undergone the rigorous safety and efficacy testing required by the FDA, providing a level of evidence and quality assurance that research peptides cannot match. If a peptide has been studied for a condition you are interested in but is not FDA-approved, that is an important distinction to understand when evaluating your options with a healthcare provider.

Which Peptides Are FDA Approved?